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Introduction 
Schiff bases are an important class of ligands both in the medic-
inal and pharmaceutical fields. The coordination to vanadium 
spread the applications to such a biological activity as antibacte-
rial, anti-inflammatory, antiviral, antifungal, anticancer and an-
tipyretic properties [1-7]. One of the significant role of vanadium 
was found recently as decreasing the resistance to oncolytic im-
munotherapy [8]. On the other hand, chemistry and properties of 
vanadium complexes with Schiff bases allowed us to study the 
possible coordination modes of vanadium, stability of its oxida-
tion states, role of co-ligands and the stability in solution [9,10].
It has been also shown that vanadium compounds are potent 
inhibitors of phosphatases, especially protein tyrosine phos-
phatases such as PTP1B, TCPTP, PTP-MEG2, SHP-1, SHP-2, 
LAR [11-13]. This leads to the modulation of various cellular 
functions and may be the basis for the therapeutic use of va-
nadium compounds in metabolic, neoplastic, inflammatory, 
neurodegenerative and other diseases. The beneficial effects 
of vanadium compounds have been observed in studies using 
cells (including cancer) and in animal studies demonstrating 
the potential therapeutic efficacy of this group of phosphatase 
inhibitors. 
Adverse and toxic effects of vanadium compounds have been 
observed in numerous preclinical, animal models during studies 
of pharmacological activity of vanadium compounds, mainly in 
antidiabetic and antitumor activity tests [14]. Numerous side and 
toxic effects of vanadium compounds affect most of the systems 
and organs of the body. This includes the respiratory, digestive 
and cardiovascular system as well as blood, brain, liver and kid-
neys. Vanadium also exhibit reproductive toxicity, influence on 
developmental processes and have potential to exert teratogenic 
and carcinogenic activity [15-17]. Several studies on preclinical 
animal models have provided strong evidence that the toxicity 
of vanadium compounds is related to several factors including 
species, dose, route and duration of administration as well as 
to the nature of the compound [18,19]. Organic vanadium com-
pounds were recognised as much safer than inorganic vanadium 
salts [20] and antidiabetic potency and efficacy as well as tox-
icity may be modified by reasonable ligand binding of vanadyl 
ions [21]. The possibility of modulating the biological effects of 
vanadium (minimizing toxic effects and preserving the phar-
macological activity) by modification the structure of organic 
ligands has been demonstrated by number of studies [22-24]. 
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Materials and Methods 
[VO(acac)2], VOSO4aq, 1,10-phenanthroline (phen), maltol, 
acetone, benzhydrazide, nicotinic hydrazide, phenylacetic hy-
drazide, 4-chlorobenzhydrazide, 2-hydroxybenzhydrazide, 
3-hydroxy-2-naphthoic acid hydrazide, and 3,5-di-tert-bu-
tyl-2-hydroxybenzaldehyde (bald) were of analytical grade 
(Aldrich) and were used as supplied. Ethanol (98%) of phar-
maceutical grade was from Polmos and used as supplied. All 
other solvents were of analytical grade and were used as sup-
plied. BaSO4 was of spectroscopic grade (Japan). Bu4NPF6 was 
synthesized from Bu4NBr and KPF6 by a standard method and 
recrystallized from acetone [25]. Microanalysis of carbon, hy-
drogen and nitrogen were performed using Elementar Vario MI-
CRO Cube elemental analyzer. IR spectra were recorded on a 
Bruker EQUINOX 55 FT-IR spectrophotometer in KBr pellets. 
The electronic absorption spectra were recorded with Shimad-
zu UV-3600 UV-Vis-NIR spectrophotometer equipped with a 
CPS-240 temperature controller. Diffuse reflectance spectra 
were measured in BaSO4 pellets with BaSO4 as a reference on 
Shimadzu 2101PC equipped with an ISR-260 integrating sphere 
attachment. The magnetic susceptibility measurements were 
performed on a SHERWOOD SCIENTIFIC magnetic suscep-
tibility balance. EPR spectra were recorded on a BRUKER 
ELEXSYS 500 using 9.419 GHz microwave frequency. Cyclic 
voltammetry measurements were carried out in DMSO with 
[Bu4N]PF6 (0.1 M) as the supporting electrolyte, using Pt work-
ing and counter and Ag/AgCl as reference electrodes on an AU-
TOLAB/PGSTAT 128 N Potentiostat/Galvanostat. E1/2 values 
were calculated from the average anodic and cathodic peak po-
tentials, E1/2 = 0.5(Ea + Ec). The redox potentials were calibrated 
versus ferrocene (0.440 V versus SHE), which was used as an 
internal potential standard for measurements in organic solvents 
to avoid the influence of a liquid junction potential; the final val-
ues are reported versus the standard hydrogen electrode (SHE).
Assessment of pharmacological activity included in vitro 
evaluation of PTP1B inhibition by an enzyme-based assay [26]. 
For determination the ability of tested compounds to inhibition 
of human recombinant PTP1B previously described method was 
used [26]. To the solution of the tested compounds on black 384-
well microplate wells (PerkinElmer) an equal volume of a test 
solution of phosphatase 50 ng mL−1 PTP1B (1.5 U ml-1) was 
added in a reaction buffer: 25 mM of 3-(N-morpholino)pro-
panesulfonic acid (MOPS), 50 mM NaCl, 1 mM dithiothreitol 
(DTT) and 0.05% Tween-20, pH 7.0. After 10 minutes, a solution 
of phosphate 6,8-difluoro-4-methyl (DiFMUP) was added until 
its final concentration was 0.1 mM. After 20 minutes of incuba-
tion at room temperature, the fluorescence intensity (excitation 
355 and emission 560 nm) was measured on a multifunctional 
plate reader POLARstar Omega (BMG Labtech, Germany). 
Cytotoxicity assay was performed using PrestoBlue Cell 
Viability Reagent (ThermoFisher Scientific), a cell permeable 
resazurin-based reagent that functions as a cell viability indi-
cator by using the reducing power of living cells (mitochondrial 
enzymes activity) to quantitatively measure the proliferation of 
cells. Human hepatocytes HepG2 seeded 18-24 hours before ex-
periments in 96-well microplate (1x103 in 100 µl DMEM with 
10% FBS) were incubated with tested compounds at 37°C and 
5% CO2. After 24 hours incubation, 10 μl of PrestoBlue reagent 
was added to each microplate well and microplate was mixed 
on orbital shaker. Plates were incubated for 20 minutes and the 
fluorescence intensity at 560 nm excitation and 590 nm emis-
sion was determined using multi-mode microplate reader PO-
LARstar Omega (BMG Labtech, Germany). The results were 
normalized to the control (cells with solvent only), wherein the 
intensity of fluorescence was taken as 100%.
Statistical analysis was performed by analysis of variance fol-
lowed by the Tukey test for post hoc comparisons using Graph-
Pad Prism 6.0 software (GraphPad Software, USA). 
Synthesis 
In Table 1 the ligand notation is shown.
Table 1. Schiff base ligands, formed in situ in reaction between 







L5 3-hydroxy-2-naphtoic acid hydrazide
L6 nicotinic hydrazide
[VO(L1)(maltol)]·H2O, 1 
The bald (0.351 g, 1.5 mmol) and the benzhydrazide (0.204 g, 
1.5 mmol) were dissolved in 33 ml of EtOH under Ar. The mix-
ture was refluxed for 10 minutes under argon, next VOSO4aq 
(0.333 g, 1.5 mmol) was added and mixture was refluxed for 15 
minutes. The solution becomes slowly dark. Then 10% from 
total 0.189 g (1.5 mmol) of maltol was added. After 5 minutes 
of reflux rest of the maltol was added. The solution becomes 
dark red. The reflux was then removed and 10% of solvent was 
evaporated under Ar. At this stage, formation of crystals was 
observed. The mixture was left for cooling. The formed dark 
red crystals were filtered off, washed with EtOH and water and 
dried in air. Yield: 0.540 g, 64 %. MW = 560.51. Anal. Cal-
cd. for C28H33N2O7V: C, 60.00; H, 5.93; N, 5.00 %. Found: C, 
60.46; H, 5.72; N, 4.95 %. The complex is diamagnetic. FT-IR 
(KBr, cm-1): 3452 (w,br), 2963 (s), 2863 (w), 1622 (s), 1606 (s), 
1591 (s), 1537 (m), 1515 (w), 1493 (w), 1462 (w), 1432 (m), 1349 
(s), 1263 (vs), 1202 (s), 930 (m), 849 (m), 696 (s), 651 (w), 591 
(w), 544 (w), 612 (s), 476 (m), [V=O] 978 (s). UV-Vis (DMSO): 
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285, 340, 464 nm, (MeCN) : 285, 340, 460 nm, (MeOH): 272, 
326, 400 nm. 
[{VO(L2)(EtO)}{V(L2)(EtO)2}(µ-O)], 2
The complex was synthesized by us in 2010 by different method 
than that described in the literature [27]. The synthesis of the 
complex was under patent procedure and we could not published 
the results before 2017. The bald (0.352 g, 1.5 mmol), 2-hydrox-
ybenzhydrazide (0.228 g, 1.5 mmol) and EtOH (30 ml) were 
refluxed for 15 minutes (yellow solution was observed). Then 
VOSO4aq (0.333 g, 1.5 mmol) was added and mixture was re-
fluxed for additional 90 minutes. The solution turned to dark 
yellow-brown and formation of yellow-brown precipitation was 
observed. The crystals were filtered off, washed with cold EtOH 
and dried in air. Yield: 0.554 g, 73 %. MW = 1002.98. Anal. 
Calcd. for C50H68N4O11V2: C, 59.88; H, 6.83; N, 5.59 %. Found: 
C, 60.08; H, 6.68; N, 5.67 %. The complex is diamagnetic. FT-
IR (KBr, cm-1): 3380 (w,br), 2965 (vs), 2862 (w), 1625 (vs), 1558 
(m), 1523 (w), 1490 (m), 1463 (w), 1385 (w), 1361 (s), 1309 (w), 
1272 (m), 1252 (vs), 1181 (m), 1091 (m), 1055 (s), 920 (m), 903 
(m), 853 (m), 753 (s), 730 (m), 690 (w), 637 (m), 621 (m), 566 (w), 
468 (w), [V=O] 993 (m), 957 (vs). UV-Vis (DMSO): 340, 416 nm, 
(MeCN) : 277, 342, 460 nm, (EtOH): 270, 338, 415 nm.
[VO(L2)2]·EtOH, 3
The bald (0.541 g, 2.3 mmol), 2-hydroxybenzhydrazide (0.351 g, 
2.3 mmol) and EtOH (30 ml) were refluxed under Ar for 15 min-
utes. Then VOSO4aq (0.513 g, 2.3 mmol) was added and reflux 
was continued for next 30 minutes. The dark green-brown prod-
uct was started to precipitate. The solution was evaporated to ca 
10 ml under argon and left for cooling. The precipitate was fil-
tered off under argon, washed with deareated acetone and dried 
under argon. Yield: 0.300 g, 31 %. MW = 845.92. Anal. Calcd. 
for C46H58N4O8V: C, 65.31; H, 6.91; N, 6.62 %. Found: C, 65.29; 
H, 6.90; N, 6.41 %. The complex is paramagnetic, µ = 1.34 µB. 
FT-IR (KBr, cm-1): 3458 (w,br), 2963 (vs), 2869 (w), 1623 (vs), 
1589 (vs), 1535 (vs), 1487 (s), 1464 (m), 1426 (w), 1388 (m), 1363 
(s), 1304 (w), 1251 (vs), 1180 (m), 1159 (m), 1030 (w), 914 (w), 829 
(m), 783 (m), 750 (s), 725 (m), 661 (m), 615 (m), 563 (m), 476 (w), 
[V=O] 954 (w). UV-Vis (DMSO): 301, 370 nm, (MeCN) : 284, 
300, 363 nm, (EtOH): 274, 303, 371 nm.
[VO(L3)(bald)], 4
The bald (0.353 g, 1.5 mmol) and the phenylacetic hydrazide 
(0.227 g, 1.5 mmol) in 50 ml of EtOH were refluxed for 10 min-
utes under Ar. Then [VO(acac)2] (0.398, 1.5 mmol) was added 
and mixture was refluxed for 38 minutes giving very dark yellow 
transparent solution. This was then evaporated to ca. 20 ml and 
left aside for crystallization. The next day black powder product 
was filtered off. Yield: 0.170 g, 34 %. MW = 665.76. Anal. Cal-
cd. for C38H50N2O5V: C, C, 68.55; H, 7.57; N, 4.21 % Found: C, 
68.35; H, 7.39; N, 4.38 %. The complex is diamagnetic. FT-IR 
(KBr, cm-1): 3470 (w,br), 2951 (vs), 2874 (w), 1650 (vs), 1609 (vs), 
1559 (s), 1546 (s), 1528 (s), 1462 (m), 1434 (s), 1391 (m), 1361 (s), 
1371 (m), 1266 (s), 1247 (vs), 1205 (m), 1172 (s), 1027 (w), 926 
(w), 913 (w), 848 (s), 811 (w), 758 (m), 729 (s), 645 (w), 624 (m), 
593 (s), 568 (m), 488 (w), [V=O] 982 (vs). UV-Vis (DMSO): 324, 
515 nm, (MeCN) : 253, 277, 507 nm, (EtOH): 272, 324, 511 nm.
[VO(L4)(phen)]·2H2O, 5
The bald (0.352 g, 1.5 mmol) and the 4-chlorobenzhydrazide 
(0.254 g, 1.5 mmol) and EtOH (50 ml) were refluxed for 10 min-
utes under Ar. Then [VO(acac)2] (0.394 g, 1.5 mmol) was added. 
The immediate change of solution colour to dark green and then 
brown was observed. The mixture was refluxed for 20 minutes 
and 1,10-phenanthroline (0.276 g, 1.5 mmol), in 10 ml of EtOH, 
was added. The solution turns to blooded-red. The solution was 
left for crystallization. The formed crystals were filtered off, 
washed with EtOH and dried in air. Yield: 0,183 g, 18 %. MW = 
668.08. Anal. Calcd. for C34H37ClN4O5V: C, 61.13; H, 5.58; N, 
8.39 %. Found: C, 60.67; H, 5.24; N, 7.50 %. The complex is par-
amagnetic, µ = 1.48 µB. FT-IR (KBr, cm-1): 3465 (s,br), 2945 (vs), 
2863 (w), 1646 (w), 1608 (vs), 1585 (s), 1519 (s), 1490 (s), 1464 
(w), 1428 (s), 1386 (m), 1364 (s), 1273 (w), 1252 (m), 1197 (w), 
1169 (m), 1142 (w), 1089 (m), 1016 (w), 913 (w), 845 (s), 781 (w), 
726 (s), 643 (w), 588 (w), 554 (w), 456 (w), [V=O] 966 (s). UV-Vis 
(DMSO): 331, 418 nm, (MeCN) : 263, 332, 421 nm, (EtOH): 230, 
265, 333, 429 nm.
[VO(L5)(EtO)], 6
The bald (0.352 g, 1.5 mmol) and the 3-hydroxy-2-naphthoic acid 
hydrazide (0.303 g, 1.5 mmol) were dissolved in 80 ml of EtOH 
under Ar flow on a magnetic stirrer. The mixture was refluxed 
for 35 minutes with constant stirring and the temperature was 
raised to 100 oC. Then VOSO4aq (0.333 g, 1.5 mmol) and 15 ml of 
EtOH were added and the mixture was refluxed for 180 minutes. 
After that, the volume of the reaction mixture was concentrated 
to final volume of ca. 20 ml and cooled to the room temperature. 
The black powder started to precipitate from dark brown solu-
tion. The precipitate was filtered off, washed with ethanol and 
dried in air. Yield: 0.614 g, 77 %. MW = 528.51. Anal. Calcd. for 
C28H33N2O5V: C, 63.63; H, 6.29; N, 5.30 %. Found: C, 63.85; H, 
6.23; N, 5.32 %. The complex is diamagnetic. FT-IR (KBr, cm-1): 
3465 (w,br), 2963 (vs), 2863 (w), 1642 (s), 1602 (s), 1575 (m), 1554 
(s), 1523 (vs), 1470 (s), 1431 (w), 1390 (w), 1363 (m), 1342 (m), 
1301 (s), 1270 (w), 1242 (m), 1215 (m), 1181 (m), 1147 (m), 1091 
(m), 1053 (vs), 997 (vs), 929 (m), 904 (m), 873 (m), 854 (m), 756 
(m), 747 (m), 707 (w), 656 (w), 642 (m), 619 (m), 569 (w), 552 (w), 
473 (w), [V=O] 951 (w). UV-Vis (DMSO): 334, 423 nm, (MeCN) 
: 226, 261, 326, 415 nm, (EtOH): 226, 269, 318, 417 nm.
[VO(L6)H2O], 7
a)  The bald (0.469 g, 2.0 mmol) and the nicotinic hydrazide 
(0.274 g, 2.0 mmol) in 40 ml of EtOH were refluxed for 15 
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minutes under Ar. Then the VOSO4aq (0.442 g, 2.9 mmol) 
was added. The reflux was continued for 25 minutes under Ar. 
The red compound was filtered off, washed several times with 
ethanol and dried in air. Yield: 0.134 g, 15 %. MW = 436.4. 
Anal. Calcd for C21H27N3O4V: C, 57.80; H, 6.24; N, 9.63 %. 
Found: C, 57.28; H, 5.84; N, 9.53 %. The complex is paramag-
netic, µ = 1.20 µB.
b)  The bald (0.703 g, 3.0 mmol) and the nicotinic hydrazide 
(0.411 g, 3.0 mmol) in 50 ml of EtOH were refluxed for 14 
minutes under Ar. Then the [VO(acac)2] (0.795 g, 3.0 mmol) 
was added. The reflux was continued for 48 minutes under 
Ar. The brown compound was filtered off, washed several 
times with ethanol and dried in room temperature. Yield: 
0.262 g, 20%. MW = 436.4. Anal. Calc. for C21H27N3O4V: C, 
57.80; H, 6.24; N, 9.63 %. Found: C, 57.22; H, 5.72; N, 10.02 
%. The complex is paramagnetic, µ = 1.20 µB. FT-IR (KBr, 
cm-1): 3435 (w,br), 2951 (vs), 2863 (w), 1615 (vs), 1533 (s), 1482 
(w), 1463 (w), 1433 (m), 1388 (w), 1362 (s), 1299 (w), 1274 
(w), 1251 (m), 1198 (m), 1177 (m), 1060 (w), 922 (w), 880 (s), 
838 (w), 779 (w), 756 (w), 725 (m), 695 (w), 549 (w), 480 (w), 
[V=O] 998 (w). UV-Vis (DMSO): 332, 420 nm, (EtOH) : 259, 
337, 457 nm.
[VO(L6)(EtO)(EtOH)], 8
The bald (0.469 g, 2.0 mmol) and the nicotinic hydrazide (0.274 
g, 2.0 mmol) in 60 ml of EtOH were refluxed for 15 minutes 
under Ar. Then the VOSO4aq (0.442 g, 2.9 mmol) was added. 
The reflux was continued for 90 minutes under Ar. The mixture 
was left for crystallization. After one day the brown crystals 
precipitated and crystals were filtered off, washed several times 
with ethanol and dried in room temperature Yield: 0.400 g, 39%. 
MW = 509.5. Anal. Calcd for C25H36N3O5V: C, 58.93; H, 7.12; 
N, 8.25 %. Found: C, 58.40; H, 6.97; N, 8.16 %. The complex is 
diamagnetic. FT-IR (KBr, cm-1): 3435 (w,br), 3104 (w,br), 2963 
(vs), 2856 (m), 1610 (vs), 1583 (m), 1555 (s), 1518 (s), 1466 (w), 
1434 (s), 1407 (m), 1379 (s), 1362 (s), 1348 (s), 1273 (m), 1251 (m), 
1209 (w), 1181 (m), 1149 (w), 1088 (s), 1052 (vs), 915 (s), 876 (w), 
848 (m), 770 (w), 755 (w), 720 (m), 702 (w), 644 (m), 620 (w), 593 
(m), 563 (m) 480 (w), [V=O] 976 (vs). UV-Vis (DMSO): 331, 422 
nm, (MeCN) : 241, 330, 417 nm, (EtOH): 333, 419 nm.
[VO(L6)(phen)]⋅5H2O, 9
The bald (0.351 g, 1.5 mmol) and the nicotinic hydrazide (0.206 
g, 1.5 mmol) in 40 ml EtOH were refluxed for 10 minutes under 
Ar. Then the VOSO4aq (0.253 g, 1.4 mmol) in 5 ml of H2O was 
added. The reflux was continued for 10 minutes under Ar. The 
1,10-phenanthroline (0.270 g, 1.5 mmol) was added. The solution 
was evaporated and the brown compound was obtained. Yield: 
0.796 g, 77 %. MW = 688.67. Anal. Calcd. for C33H43N5O8V: C, 
57.55; H, 6.29; N, 10.17 %. Found: C, 57.76; H, 5.51; N, 9.86 %. 
The complex is paramagnetic, µ = 1.34 µB. FT-IR (KBr, cm-1): 
3441 (w,br), 3064 (w), 2951 (vs), 2869 (w), 1683 (m), 1607 (vs), 
1536 (vs), 1464 (m), 1429 (vs), 1388 (w), 1363 (s), 1311 (w), 1284 
(w), 1249 (w), 1232 (w), 1199 (w), 1174 (s), 1106 (w), 1027 (s), 845 
(s), 784 (w), 770 (w), 727 (vs), 644 (w), 624 (w), 580 (m), 545 (w), 
481 (w), [V=O] 962 (s). UV-Vis (DMSO): 334, 428 nm, (MeCN) 
: 226, 287, 342, 442 nm, (EtOH): 226, 268, 337, 445 nm.
[VO(L2)(maltol)], 10 and [VO(L3)(bpy)]·MeOH, 11
The syntheses and physicochemical characterization of the 10 
and 11 complexes were described and discussed in [28]. In this 
paper we present the pharmacological activity of these com-
pounds.
Crystallographic data collection and structure 
refinement
Crystal data, data collection and structure refinement details 
are summarized in Table 2. Positions of all of non-hydrogen at-
oms were determined by direct methods using SHELXT2017 
[29]. All non-hydrogen atoms were refined anisotropically using 
weighted full-matrix least-squares on F2. Refinement and fur-
ther calculations were carried out using SHELXL2017 [30]. All 
hydrogen atoms joined to carbon atoms were positioned with 
an idealized geometries and refined using a riding model with 
Uiso(H) fixed at 1.5 Ueq of C for methyl groups and 1.2 Ueq of C 
for other groups.
Results and Discussion 
The Schiff base formed in situ in EtOH solution reacts with the 
appropriate vanadium substrate, yielding the complexes 1-9. We 
used two different V(IV) sources – [VO(acac)2] or VOSO4aq 
and it was found that the product formula does not depend on 
substrate, as shown in synthesis of 7. But in some cases, the sol-
ubility of VOSO4 is low in EtOH, resulting in formation of un-
dissolved substrate, which can contaminates the product. Thus 
the time of reflux had to be carefully controlled. As the ligand 
Ln (n = 1-6) is tridentate, the complex needs a co-ligand to fill 
the coordination sphere. When additional co-ligand is not add-
ed, vanadium coordinates or solvent molecule (as in case of 2, 
6-8) or ligand Ln (complex 3) or its components (complex 4). The 
coordination of solvent molecule results in redox instability of 
the product and the oxidation to V(V) in most cases is observed 
(complexes 2, 6, 8). Also maltol as co-ligand does not stabilize 
the +4 oxidation state (complex 1). When phen was used (com-
plexes 5 and 9), the complexes are fairly stable in air and can be 
kept in air for long period (within 9 years after preparation only 
a small decrease in magnetic moment is observed).
1. Crystal structure 
A single crystal X-ray study reveals that the asymmetric part of 
the unit cell of the complex, [VO(L6)(EtO)(EtOH)] (8), where 
L6 = N’-[(E)-(2-hydroxy-3,5-ditertbuthylphenyl)metylidene] 
pyridine-3-carbohydrazide consists of one crystallographical-
J. Szklarzewicz et al.   |   Tridentate hydrazido-hydrazones vanadium complexes. Synthesis, properties and biological activity 13
Sci, Tech. Innov 2019; 4 (1), 9-20www.stijournal.pl
ly independent VV ion surrounded by oxo ligand, one L6 ligand 
molecule, one ethoxy ligand (EtO-) and one ethanol molecule. 
The asymmetric unit of the complex with the adopted atomic 
numbering scheme is shown in Fig. 1. The crystallographic data 
and detailed information on the structure solution and refine-
ment for 8 are given in Table 2. Selected bond distances and 




Crystal system, space group Monoclinic, P21
Temperature (K) 293(2)




Radiattion type Mo Kα
µ (mm-1) 0.406 
Crystal size (mm) 0.46 x 0.23 x 0.04
Data collection
Diffractometer Nonius Kappa CCD
Absorption correction Semi-empirical from equivalents
Tmin, Tmax 0.8356, 0.984
No. of measured, independent and 
observed [I >2σ(I)] reflections 23447, 6092, 5571
Rint 0.0492
(sin θ/λ)max (Å-1) 0.649
Refinement
R[F2 >2σ(F2)], wR(F2), S 0.0371, 0.0908, 1.026
No. of reflections 6092
No. of parameters 346
No. of restraints 2
H-atom treatment H atoms treated by a mixture of independent and constrained refinement
Δ ρmax, Δ ρmin (e Å-3) 0.386 -0.258 
Table 2. Experimental details for complex 8.
Figure 1. A view of the coordination environment of the VV atom in 8. H atoms have been omitted for clarity. 
Displacement ellipsoids are drawn at the 30% probability level. The figure was prepared using DIAMOND [31]
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In the structure surroundings of the central VV form a distort-
ed octahedral O5N conformation. The equatorial plane defined 
by atoms O18, O8 and N10 of the fully deprotonated tridentate 
hydrazone ligand (L6) and O27 of ethoxy group (r.m.s. = 0.0183 
Å). The oxo O33 atom and atom O30 of the ethanol molecule 
occupy the apical sites of the octahedron with a trans angle of 
171.3(1)̊ . The central vanadium atom is above the basal plane by 
0.301 (1) Å and is directed towards the oxo O33 atom. As a con-
sequence, the O33 ligand is significantly closer to the VV cation 
than the other groups, and for the complex the V–Ooxo distance 
is equal to 1.589(2) Å, which is in agreement with data for oth-
er pentacoordinate oxovanadium(V) compounds [32-34]. In the 
complex the four V–O bond lengths are unequal, with the V=O 
bond being the shortest and the V–O30 = 2.336(2) Å (enolate) 
bond the longest. The magnitude, 2.113(2) Å, of the V1-N10 
bond indicates a low affinity between the imine N atom and the 
central atom in neutral oxidovanadium(V) complexes. The V–O 
bond lengths follow the order: V–O33oxo > V–O27ethoxo > V–
O18phenoxo > V–O8alkoxo > O30enolate. These data indicate 
stronger binding of the alkoxo group compared to the enolate 
oxygen atoms. Analysis of the crystal structure of 8 at the su-
pramolecular level reveals that the complex molecules are held 
together by typical hydrogen and two π⋅⋅⋅π interactions (Fig. 2), 
which are summarized in Tables 4 and 5, respectively. All these 
interactions are responsible for the self-assembly of the complex 
molecules and stabilization of the 3D structure.
Table 4. Hydrogen-bond geometry (Å, °)
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
O30-H30⋅⋅⋅N4i 0.94(3) 1.90(3) 2.834(4) 169(5)
Symmetry codes: (i) x - 1, y, z 
Table 5. π⋅⋅⋅π interaction geometry in 8 (Å).  





Symmetry codes: (i) x - 1, y, z; (ii) x + 1, y, z
2. UV-Vis spectra
The UV-Vis spectral data are collected in Synthesis for each 
complex. As the solubility of the complexes is poor, only inter 
ligand transitions are observed, the less energetic one is con-
nected with the formation of imine group within Schiff base. 
The more interesting thus are the spectra in solid state, in which, 
due to the technique used, the low intensity d-d transitions can 
be also observed. The reflectance spectra, after Kubelka-Munk 
transformation, are presented separately for diamagnetic (Fig. 
3) and paramagnetic (Fig. 4) complexes. The presented spectra 
are very similar to that in solution, for paramagnetic complexes 
the d-d bands are better visible, as in solution these forbidden 
transitions have a very low intensity, compared to allowed CT 
ones.
Figure 2. The 3D supramolecular network of 8 formed through O-H⋅⋅⋅N and 
π⋅⋅⋅π interactions. [Symmetry codes: (i) x - 1, y, z; (ii) x + 1, y, z]. The figure 
was prepared using DIAMOND [31]
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3. Magnetic measurements
To find the exact oxidation state of vanadium, the magnetic 
susceptibility measurements were performed using a magnetic 
Ewan’s balance. The calculated magnetic moments are present-
ed in the Experimental part. Complexes 1, 2, 4, 6 and 8 were 
diamagnetic, while the magnetic moment of complexes 3, 5, 7 
and 9 indicate on V(IV) with d1 configuration. The EPR spectra 
of complexes, were measured both at room and at liquid nitro-
gen temperature for solid samples and are in agreement with 
the magnetic susceptibility data. The EPR spectra at room tem-
perature show g parameter equal to 1.978 (3), typical for vana-
dium(IV). The absence of hyperfine structure indicates on V-V 
interaction in condensed phase, both at room and at liquid nitro-
gen temperature.
4. Thermogravimetry
Thermal decomposition processes for complexes 3 and 9 are pre-
sented in Fig. 5, while numerical data are collected in Table 6.
The decomposition of complex 3 starts early, the final mass 
loss is 90.17 %, calculated for EtOH and ligand release is 92.09, 
these both values fit quite well including oxidation processes 
and formation of V2O5 as a final product. For complex 9 several, 
not well resolved, decomposition processes can be seen in Fig. 5. 
The raft estimations gave in Table 6 show that water is released 
in two separated steps and then phen ligand is released. As the 
plateaus are not well reached (see Fig. 5) the mass loss can only 
be estimated (basing on SDTA plots). The next step is two-step 
decomposition of ligand L, probably, as indicated in Table 6, 
first hydrazide and then in second step aldehyde part of the li-
gand are released. Such a stepwise decomposition of Schiff base 
ligand was observed earlier by us [9,10,26]. The total mass loss 
is 96.90 %, calculated 93.03 %.
Figure 3. Reflectance spectra (after Kubelka-Munk transformation) of 
diamagnetic complexes 1, 2, 4 and 6. BaSO4 as internal white standard
Figure 4. Reflectance spectra (after Kubelka-Munk transformation) of 
paramagnetic complexes 3, 5, 7 and 9. BaSO4 as internal white standard
Figure 5. TG (left axis) and SDTA (right axis) curves for 3 (left) and 9 (right). Scan speed 10o / min, air
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5. Cyclic voltammetry
Cyclic voltammograms for selected complexes are presented in 
Figs. 6 and 7. In general the presented data indicate on irre-
versible processes connected with the vanadium oxidation (at 
positive potentials), this is a typical behavior for vanadyl com-
pounds. The reversible redox processes at negative potentials 
are observed for complexes with bidentate co-ligands (1, 3, 4 
and 5), as exemplified in Fig. 7. This behavior was found earlier 
by us for complexes with phen as a co-ligand, the E1/2 = -1.31 
V for 5 (with Ea/Ec peak separation of 110 mV at scan speed 
100 mV/s). Similar behavior shows the complex 1 with maltol 
as a co-ligand with E1/2 = -0.116 V and Ea/Ec peak separation 
of 73 mV (at scan speed 100 mV/s), indicating on one electron 









































* – rest of the peaks, shown in Fig. 5 were not listed, a Δm calculated for release of hydrazide part of the ligand, b Δm calculated for 
release of the aldehyde from the ligand.
Table 6. The TG and SDTA data for complexes 3 and 9. Scan speed 10o /min.
Figure 6. Cyclic voltammograms of complexes 2, 6, 7 and 8 in DMSO. Pt working and counting, Ag/AgCl as reference electrodes. 
Potentials versus SHE. 0.1M Bu4NPF6, scan speed (full curve) 100 mV/s, insets scan speeds from 20–1000 mV/s
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process. The independence of E1/2, Ea and Ec on scan speed and 
symmetry of peaks support the reversibility of the redox pro-
cess. The electrochemical reversibility observed for complexes 
3 and 4 are directly connected with bidentate co-ligand (bald 
for 4, and bidentate L2 ligand in 3). The E1/2 = -0.782 V (Ea/Ec 
peak separation 130 mV) for 3 and E1/2 = -0.059 V (Ea/Ec peak 
separation 94 mV) at scan speed 100 mV/s. For 4 the reversi-
ble process is connected with coordination of bald, much lower 
potential observed for 3 with the L2 ligand indicates that the 
hydrazide part (different in 3 and 4) stabilizes the aldehyde part 
of Schiff base. In case of ligand L2 (in complex 3) aromatic ring 
of hydrazide stabilizes the aldehyde part, while when aliphatic 
separator between aromatic ring and hydrazide part (as in li-
gand L3) is present, such a stabilization is not observed, and in 
4 redox processes are less energetic.
6. Complex stability in solution
The admission of vanadium complexes in in vitro and in vivo 
studies complicates theirs solubility, stability on transfer 
through digestion system (with pH as low as 2.0) and transfer to 
the cell. Due to the almost insolubility in water of synthesized 
complexes, we were forced to use DMSO as a solvent in the mix-
ture with water. DMSO is very popular in medicine as it helps 
in transfer of many substances through biological membranes. 
However, in in vitro studies, the main medium for cells is water 
(as solvents for all biological buffers and media). We firstly stud-
ied the stability of the complexes in pure DMSO, by measuring 
the UV-Vis spectra versus time. We have found, that the solu-
tions of all 1-9 complexes are stable in DMSO. In DMSO-H2O 
(20 µl + 3ml, respectively) mixtures at native pH complexes are 
fairly stable and only small decomposition is observed (less than 
10% of decomposition after 90 min). At pH = 2.00 complexes 5 
and 7 are stable, while others undergoes slow decomposition, 
still over 50% of initial complex amount remains after 90 min-
utes. All these facts indicate, that all studied complexes are sta-
ble enough to survive the conditions present in human digestion 
system. The sample spectra changes for complex 6 are presented 
in Fig. 8.
Figure 7. Cyclic voltammograms of complexes 1, 3, 4 and 5 in DMSO. Pt working and counting, Ag/AgCl as reference electrodes. 
Potentials versus SHE. 0.1M Bu4NPF6, scan speed (full curve) 100 mV/s, insets scan speeds from 20–1000 mV/s.
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Biological activity of selected complexes
All tested complexes (2, 3, 5, 7, 9-11) as well as comparative 
compounds (VOSO4, BMOV and suramin) were shown the in-
hibitory effect on human recombinant PTP1B at 100 μM con-
centration (P≤.001) as shown in Fig. 9. All complex showed a 
weaker degree of inhibition both to the inorganic vanadium ref-
erence compound and to the organic vanadium complex BMOV 
[bis(maltolato)oxovanadium(IV)] whose pharmacological activ-
ity has been extensively studied and which has been in phase III 
clinical trials. The compounds 5 and 9 have been shown a signif-
icantly more potent PTP1B inhibition ability than the other test-
ed compounds and over twice higher inhibition than suramin. 
The very important part in application of compounds is their 
cytotoxicity. The cytotoxicity of tested compounds on HepG2 
hepatocytes is presented in Fig. 10. The results were normalized 
to the control (cells with solvent only), wherein the intensity of 
fluorescence was taken as 100%. The complex 3 does not show 
significant cytotoxicity compared to control and to VOSO4 or 
BMOV, while all other complexes possesses high cytotoxicity.
Conclusions
Nine new complexes of vanadium with ONO donating Schiff 
hydrazido-hydrazones are described and characterized. All 
complexes contain the V=O group. The bidentate co-ligands not 
only stabilize the V(IV) oxidation state, but also stabilize com-
plexes in solution, even at pH 2.00. The stabilization at low pH 
is very important in vanadium applications as pharmaceuticals. 
In contrary to bidentate ligands, as in BMOV, coordination of 
tridentate ligand results in strong dependence of biological ac-
tivity (cytotoxicity and inhibition of human PTP1B) on type of 
ligand used. This, together with complex stability, indicates that 
ONO ligand is not released during migration to the cells and the 
biological activity depends on ONO ligand composition and not 
only on presence of VO2+ anions. Further studies are in progress. 
Figure 8. UV-Vis spectra of complex 6 in DMSO-H2O mixture (20 µl + 3 ml respectively) mixture at native pH (left) and  
at pH = 2.00 (right). T = 37 oC, d = 1 cm, 15 spectra measured in 340 s intervals. The arrow shows direction of changes in spectra
Figure 9. Inhibition of human PTP1B. Error bars: +/− SD. Statistically 
significant differences in comparison to control: *** p = 0.0001 (for VOSO4, 
BMOV, suramin, 2, 5, 7, 9, 10, 11), *p = 0.01 (for 3)
Figure 10. Cytotoxicity of tested compounds on HepG2 hepatocytes. Error 
bars: +/− SD. Statistically significant differences in comparison to control: 
*** p = 0.0001 (for 2, 7, 9 and 10)
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